Wedbush Lowers Earnings Estimates for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Wedbush reduced their Q1 2025 earnings estimates for Travere Therapeutics in a research note issued on Monday, February 24th. Wedbush analyst L. Chico now expects that the company will earn ($0.43) per share for the quarter, down from their previous forecast of ($0.42). The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.56) EPS.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The firm had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%.

TVTX has been the topic of several other research reports. Evercore ISI boosted their price target on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Piper Sandler upped their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. HC Wainwright increased their price target on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Finally, Citigroup lifted their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Stock Up 1.8 %

Shares of TVTX opened at $21.03 on Thursday. The firm has a 50 day simple moving average of $19.90 and a two-hundred day simple moving average of $16.89. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics has a one year low of $5.12 and a one year high of $25.29. The company has a market cap of $1.64 billion, a P/E ratio of -5.13 and a beta of 0.72.

Hedge Funds Weigh In On Travere Therapeutics

Large investors have recently modified their holdings of the company. Entropy Technologies LP bought a new stake in Travere Therapeutics during the 4th quarter worth approximately $214,000. Aigen Investment Management LP purchased a new position in shares of Travere Therapeutics during the 3rd quarter valued at $170,000. Oppenheimer & Co. Inc. bought a new position in shares of Travere Therapeutics in the third quarter worth $673,000. FMR LLC raised its position in shares of Travere Therapeutics by 27.5% in the third quarter. FMR LLC now owns 147,416 shares of the company’s stock worth $2,062,000 after buying an additional 31,772 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its stake in Travere Therapeutics by 30.2% during the third quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after buying an additional 167,100 shares during the period.

Insider Buying and Selling

In other news, SVP William E. Rote sold 2,437 shares of Travere Therapeutics stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the transaction, the senior vice president now directly owns 83,170 shares in the company, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the sale, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,335 shares of company stock valued at $4,453,012. Company insiders own 4.06% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.